Blossom covers the latest that goes on with psychedelic research. We make the waterfall of new papers easier to digest, for both laypeople, psychedelic entrepreneurs, and researchers alike. We provide handy overview posts every month and research highlights every second week.
Need an overview of where the research stands at this moment? Dive in with our Research Overview.
In the Research Briefing of January 10th: 1) Psilocybin can be administered safely for up to six people simultaneously 2) An Open Science approach toward MDMA synthesis 3) Nitrous Oxide could be the next antidepressant
December was another busy month in the world of psychedelic research as 2021 came to a close. The benefits of microdosing remain in dispute, the use of virtuality reality in tandem with psychedelics is further discussed, while we simultaneously gained further insight as to how different psychedelics work in the brain for different disorders, through both experiments and reviews.
To better understand the science of psychedelics, and how we can make the bridge to implementing them in practice, Blossom is conducting a series of interviews with psychedelic scientists. Our editor-at-large, George Fejer, speaks to David Glowacki, one of the world's leaders in the use of virtual reality applied to scientific simulation and visualization.
Microdosing is becoming more popular every day. From Hollywood to small towns all across the word. Is there scientific merit to it, or all placebo? And does a new paper prove the benefits of microdosing?
November proved to be another productive month for psychedelic research. A variety of surveys looked at how psychedelics alter beliefs, reduce opioid use, and the effects of microdosing. A finished Phase I trial clear 5-MeO-DMT for the next step, cannabis intensifies a psychedelic experience, and psychedelics may help with Alzheimer's.
In the Research Briefing of December 6th: 1) The methodological challenges faced in psychedelic clinical trials (and how to fix them) 2) Mystical experiences in recreational use associated with improvements in wellbeing 3) A novel 5-MeO-DMT formulation proves to be safe in Phase I trial
This is all the other psychedelic research that came out in December 2021.
Blossom‘s articles cover everything from the latest paper (also featured individually in our Papers Database) to analyses of research fields. From MDMA-AT for PTSD to psilocybin for TRD. We will pick apart the industry terms, e.g. MDMA-AT = MDMA-assisted therapy
Become a psychedelic insider!
With a free Blossom membership you will always be in the know.
📰 Weekly newsletter about the psychedelic research
✔️ Unlimited access to our database and original articles